Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancerNicolò Matteo Luca Battisti, Alistair Ring, Stephanie Mappouridou et al.|Breast Cancer Research and Treatment|2021Cited by 74